Boron and Zinc Co-doped Hydroxyapatites for Bone Tissue Engineering Applications.
Akbaba S., Turacli Karaguven SO., Evis Z., Tezcaner A.
Laboratory Study, published in Biol Trace Elem Res (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Biol Trace Elem Res (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40742644
- DOI
- 10.1007/s12011-025-04756-1
- Citations
- 2
Abstract (original English)
In this study, effects of B and Zn co-doping on structural and biological properties of hydroxyapatite (HA) were investigated. Effect of co-doping on synthesized HA groups was characterized by SEM, ICP-OES, XRD, FTIR, and dynamic light scattering. It was revealed that 8 mol% B led to a decrease in particle size, whereas increasing Zn resulted in increasing mean particle size. FTIR spectra verified presence of PO 4 3- and BO 3 3- in the HA structure. XRD analysis revealed that both B and Zn decreased HA phase percentage, crystallinity and crystallite size. Bioactivity of the HA groups increased with presence of B and Zn. Dual effect of B and Zn on viability and proliferation of human adipose derived stem cells (hADSCs) was also investigated. It was found that 8 mol% B doped and all B & Zn-doped HA groups increased cell viability and proliferation, except 8 mol% B & 8 mol% Zn doped HA. Moreover, 0.5 mg/ml 8 mol% B & 4 mol% Zn doped HA group significantly increased 14-day ALP activity of hADSCs and vessel area of human umbilical vein endothelial cells (HUVECs). Overall, Co-doping of B (8 mol%) and Zn (4 mol%) to HA provided both proliferative and osteogenic effects on hADSCs and angiogenic effect on HUVECs. Our findings suggest that B and Zn co-doped HA holds promise for bone tissue engineering applications.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.